Shenda Baker, Ph.D.
President, Chief Operating Officer, Synedgen
Dr. Shenda Baker is President, Chief Operating Officer, Treasurer and Co-founder of Synedgen Inc. Dr. Baker has more than 25 years of experience in polymer chemistry and materials science and in leading, funding, and directing scientific research and development. She has extensive experience managing project execution, external consultants and advisors and business development efforts. Previously, Dr. Baker served as President of BioSTAR West, and as the lead scientific advisor to Hawaii Chitopure and Professor of Chemistry at Harvey Mudd College. Dr. Baker served on the Board of Directors of the Materials Research Society and has served on advisory boards with the National Institutes of Health, National Science Foundation and the Department of Energy. Dr. Baker is a member of the American Chemical Society and the Materials Research Society and currently serves on the Advisory Council of the National Institute of Dental and Craniofacial Research of the NIH. She is co-inventor on all Synspira technology.
Mr. Glenn Batchelder is Chairman of the Board for RESET Therapeutics and XyloCor Therapeutics. Mr. Batchelder was Co-Founder and CEO of Civitas Therapeutics, a development stage pulmonary delivery therapeutic company based on the ARCUS technology platform that was sold to Accorda Therapeutics. Prior to Civitas he also served as CEO of BIND Biosciences (sold to Pfizer), CEO of Acceleron Pharma (NASDAQ: XLRN) and SVP of Operations at Millennium Pharmaceuticals (sold to Takeda). During his more than 30 years of executive leadership experience he also served in functional roles including sales, marketing, business development, manufacturing, supply chain management and R&D. He also serves on the non-profit board of directors for the Michael J. Fox Foundation for Parkinson’s Research and The Possible Project. He is the former Chairman of the MassBio board.
President and Chief Executive Officer, Synspira Therapeutics
Robert Gallotto serves as President and chief executive officer of Synspira Therapeutics. Mr. Gallotto is an experienced pharmaceutical executive, with a 30-year record of building companies focused in cystic fibrosis and other rare diseases. Prior to joining Synspira, Mr. Gallotto was the co-founder and served as President of Alcresta Therapeutics, a company focused on developing products for cystic fibrosis and other rare diseases. Mr. Gallotto built the company from an idea to the successful launch of its first product, RELiZORB, a novel medical device awarded the 2016 Medical Device Design Excellence Gold Medal Award. Mr. Gallotto has been involved with several collaborations with the CF Foundation over the past 20 years and is the inventor of numerous issued patents. Mr. Gallotto also served as co-founder and chief operating officer of Allena Pharmaceuticals. Prior to Alcresta and Allena, Mr. Gallotto served as chief business officer of Alnara Pharmaceuticals, until the company was acquired by Eli Lilly. Mr. Gallotto also served as vice president of strategic planning, business and commercial development for Altus Pharmaceuticals. Before joining Altus, Mr. Gallotto served in various positions in sales and marketing, business development and product management with companies such as Biogen, Ares-Serono, Sage BioPharma and The Upjohn Company. Mr. Gallotto holds a B.S. in biology from Stonehill College.
Andrew W. Miller
Mr. Andrew W. Miller is President and CEO of Stimson Lumber Company in Portland, Oregon. Prior to joining Stimson in 1991, Mr. Miller was employed in the Forest Products Industry with Plum Creek Timber and Weyerhaeuser. He holds an undergraduate degree from Grinnell College and an MBA from Columbia University. Mr. Miller serves on multiple regional and national industry association Boards, and several non-profit Boards in the Portland area. He also serves on the Board of Directors at Synedgen.
William Wiesmann, M.D.
Chairman of the Board
Dr. William Wiesmann is Chairman of the Board of Synspira. Previously, he served as the Director for Combat Casualty Care at the U.S. Army Medical Research and Materiel Command Post, at Ft. Detrick, where he led the design and development teams that produced novel medical technologies. He is a member of the University of Cincinnati Department of Biomedical Engineering External Advisory Board and a member of the National Council at Washington University School of Medicine. He is a Trustee Emeritus at Harvey Mudd College in Claremont, California and recently served as an Ethan A.H. Shepley Trustee at Washington University. In 2008 he received an honorary doctorate of science from the University of Cincinnati recognizing his accomplishments in military and civilian trauma medicine. Dr. Wiesmann is a co-inventor of all Synspira technology.